1. Castaigne S, Chomienne C, Daniel MT et al. All‑trans retinoic acid as a differentiation therapy of acute promyelocytic leukemia. I. Clinical Results. Blood 1990; 76: 1704–1709.
2. Frankel SR, Eardley A, Lauwers G et al. The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann Intern Med 1992; 117: 292–296.
3. Frankel SR, Eardley A, Heller G et al. All‑trans retinoic acid for acute promyelocytic leukemia. Results of the New York study. Ann Intern Med 1994; 120: 278–286.
4. Fenaux P, Le Deley MC, Castaigne S et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993; 82: 3241–3249.
5. Vahdat L, Maslak P, Miller WH et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low‑dose chemotherapy, PML/RAR-α isoform, and CD13 express-ion in patients treated with all‑trans retinoic acid. Blood 1994; 84: 3843–3849.
6. De Botton S, Dombret H, Sanz M et al. Incidence, clinical features, and outcome of all trans‑retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood 1998; 92: 2712–2718.
7. Tallman MS, Andersen JW, Schiffer CA et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoid acid syndrome. Blood 2000; 95: 90–95.
8. Matikainen S, Tapiovaara H, Vaheri A et al. Activation of interleukin-1 beta gene expression during retinoic acid‑induced granulocytic differentiation of promyeloid leukemia cells. Cell Growth Differ 1994; 5: 975–982.
9. Di Noto R, Schiavone EM, Ferrara F et al. All‑trans retinoic acid promotes a differential regulation of adhesion molecules on acute myeloid leukemia blast cells. Br J Haematol 1994; 88: 247–255.
10. Cavenagh JD, Gordon-Smith EC, Gibson FM et al. Acute myeloid leukemia blast cells bind to human endothelium in vitro utilizing E-selectin and vascular cell adhesion molecule-1 (VCAM‑1). Br J Haematol 1993; 85: 285–291.
11. Stucki A, Rivier AS, Gikic M et al. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood 2001; 97: 2121–2129.
12. Steeber DA, Tang ML, Green NE et al. Leukocyte entry into sites of inflammation requires overlapping interactions between the L-selectin and ICAM‑1 pathways. J Immunol 1999; 163: 2176–2186.
13. Rodriguez-Cimadevilla JC, Beauchemin V, Villeneuve L et al. Coordinate secretion of interleukin-1 beta and granulocyte-macrophage colony-stimulating factor by the blast cells of acute myeloblastic leukemia: role of interleukin-1 as an endogenous inducer. Blood 1990; 76: 1481–1489.
14. Oster W, Cicco NA, Klein H et al. Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. J Clin Invest 1989; 84: 451–457.
15. Delwel R, van Buitenen C, Salem M et al. Interleukin-1 stimulates proliferation of acute myeloblastic leukemia cells by induction of granulocyte-macrophage colony-stimulating factor release. Blood 1989; 74: 586–593.
16. Sanz MA, Martín G, González M et al. Risk-adapted treatment of acute promyelocytic leukemia with all‑trans‑retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004; 103: 1237–1243.
17. Didisheim P, Trombold JS, Vandervoort LE et al. Acute promyelocytic leukemia with fibrinogen and factor V deficiencies. Blood 1964; 23: 717–728.
18. Drapkin RL, Gee TS, Dowling MD et al. Prophylactic heparin therapy in acute promyelocytic leukemia. Cancer 1978; 41: 2484–2490.
19. Cordonnier C, Vernant JP, Brun B et al. Acute promyelocytic leukemia in 57 previously untreated patients. Cancer 1985; 55: 18–25.
20. Rodeghiero F, Avvisati G, Castaman G et al. Early deaths and anti‑hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 1990; 75: 2112–2117.
21. Goldberg MA, Ginsburg D, Mayer RJ et al. Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia? Blood 1987; 69: 187–191.
22. Keane TJ, Gorman AM, O’Connell LG et al. Epsilon-amino-caproic acid in the management of acute promyelocytic leu-kaemia. Acta Haematol 1976; 56: 202–204.
23. Avvisati G, ten Cate JW, Büller HR et al. Tranexamic acid for control of haemorr-hage in acute promyelocytic leukaemia. Lancet 1989; 2: 122–124.
24. Hoyle CF, Swirsky DM, Freedman L et al. Beneficial effect of heparin in the management of patients with APL. Br J Haematol 1988; 68: 283–289.
25. Gralnick HR, Abrell E. Studies of the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukemia. Br J Haematol 1973; 24: 89–99.
26. Bauer KA, Rosenberg RD. Thrombin generation in acute promyelocytic leukemia. Blood 1984; 64: 791–796.
27. Bennett M, Parker AC, Ludlam CA. Platelet and fibrinogen survival in acute promyelocytic leukemia. Brit Med J 1976; 2: 565.
28. Avvisati G, ten Cate JW, Sturk A et al. Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia. Br J Haematol 1988; 70: 43–48.
29. Sakata Y, Murakami T, Noro A et al. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood 1991; 77: 1949–1957.
30. Sterrenberg L, Haak HL, Brommer EJ et al. Evidence of fibrinogen breakdown by leukocyte enzymes in a patient with acute promyelocytic leukemia. Haemostasis 1985; 15: 126–133.
31. Imaoka S, Ueda T, Shibata H et al. Fibrinolysis in patients with acute promyelocytic leukemia and disseminated intravascular coagulation during heparin therapy. Cancer 1986; 58: 1736–1738.
32. Menell JS, Cesarman GM, Jacovina AT et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999; 340: 994–1004.
33. Brower MS, Harpel PC. Proteolytic cleavage and inactivation of α2–plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase. J Biol Chem 1982; 257: 9849–9854.
34. Kawai Y, Watanabe K, Kizaki M et al. Rapid improvement of coagulopathy by all‑trans retinoic acid in acute promyelocytic leukemia. Am J Hematol 1994; 46: 184–188.
35. Zokas L, Glenney JR Jr. The calpactin light chain is tightly linked to the cytoskeletal form of calpactin I: studies using monoclonal antibodies to calpactin subunits. J Cell Biol 1987; 105: 2111–2121.
36. Levin MD, Betjes MG, V d Kwast TH et al. Acute renal cortex necrosis caused by arterial thrombosis during treatment for acute promyelocytic leukemia. Haematologica 2003; 88: ECR21.
37. Hashimoto S, Koike T, Tatewaki W et al. Fatal thromboembolism in acute promyelocytic leukemia during all‑trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. Leukemia 1994; 8: 1113–1115.
38. Tsukada N, Wada K, Aoki S et al. Induction therapy with all‑trans retinoic acid for acute promyelocytic leukemia: a clinical study of 10 cases, including a fatal case with thromboembolism. Intern Med 1996; 35: 10–14.
39. Avvisati G, Lo Coco F, Diverio D et al. AIDA (all‑trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: A Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) pilot study. Blood 1996; 88: 1390–1398.
40. Sanz MA, Tallman MS, Lo-Coco F. Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood 2005; 105: 3019–3025.
41. Sanz MA, Lo Coco F. Standard practice and contoversial issues in front‑line therapy of acute promyelocytic leukemia. Haematologica 2005; 90: 840–845.
42. Adès L, Chevret S, Raffoux E et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2006; 24: 5703–5710.
43. Barbui T, Finazzi G, Falanga A. The impact of all‑trans‑retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998; 91: 3093–3102.